These VCs don’t wait for biotech startups to come to them. They create companies themselves.
Antonio RegaladoFollow @twitterapi
Senior Editor, Business
I am the business editor of MIT Technology Review. I look for stories about how technology is changing business. Before joining MIT Technology Review in July 2011, I lived in São Paulo, Brazil, where I wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, I was the science reporter at the Wall Street Journal and later a foreign correspondent.
Antonio Regalado's Stories
Researchers find a way to turn pain on, and off, with a beam of light.
Claims for a new, simple, technique to create stem cells.
A new company launched by Google will seek to extend human life spans.
Reading the DNA of fetuses is the next frontier of the genome revolution. Do you really want to know the genetic destiny of your unborn child?
Putting genome data into the public domain advances science, but nearly all of it can be linked to someone.
By reviving lost species, a new company could put a warm and fuzzy face on advanced reproductive engineering.
Advances in genetic engineering have some biologists convinced they’ll re-create extinct species.
An ultrathin electrode spun from a single carbon fiber can record neurons in living animals.
J. Craig Venter may have just started a race to discover alien life on the Red Planet.